STOCK TITAN

Artiva CMO sells 429 shares after option exercise

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee exercised employee stock options for 429 shares of common stock at an exercise price of $1.92 per share and immediately sold 429 shares of common stock at $12.00 per share on 2026-08-18. Following the option exercise, Banerjee held 79,571 stock options. The transactions occurred pursuant to a Rule 10b5-1 Plan adopted on May 14, 2026. The option grant vested 25% on April 8, 2026, with the remaining shares vesting monthly over the following 36 months.

Positive

  • None.

Negative

  • None.
Insider Banerjee Subhashis
Role Chief Medical Officer
Sold 429 shs ($5K)
Approx. gross sale proceeds $5K
Approx. exercise cost $823.68
Approx. pre-tax spread $4K
Type Security Shares Price Value
Exercise Employee Stock Option (Right to Buy) F1, F2 429 $0.00 $0.00
Exercise Common Stock F1 429 $1.92 $823.68
Sale Common Stock F1 429 $12.00 $5K
Holdings After Transaction: Employee Stock Option (Right to Buy) — 79,571 contracts (Direct); Common Stock — 144,963 shares (Direct)
Footnotes (2)
  1. F1. The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.
  2. F2. 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.
Options Exercised 429 shares Employee stock options exercised into common stock on 2026-08-18
Exercise Price $1.92 per share Exercise price of employee stock options converted on 2026-08-18
Sale Price $12.00 per share Price for sale of 429 ARTV common shares on 2026-08-18
Shares Sold 429 shares Common stock sold in open market or private transaction on 2026-08-18
Options Held After Transaction 79,571 shares Total stock options remaining after the reported exercise
Initial Vesting Date April 8, 2026 Date when 25% of the option grant vested and became exercisable
Vesting Schedule Duration 36 months Remaining option shares vest 1/36th per month over this period
Rule 10b5-1 Plan Adoption Date May 14, 2026 Date the reporting person adopted the trading plan governing these transactions
Rule 10b5-1 Plan regulatory
"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Employee Stock Option financial
"security_title: Employee Stock Option (Right to Buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
vested and became exercisable financial
"25% of the shares initially subject to the option vested and became exercisable"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

What insider transaction did ARTV’s Chief Medical Officer report on this Form 4?

ARTV’s Chief Medical Officer Subhashis Banerjee exercised 429 stock options at $1.92 per share and sold 429 common shares at $12.00 per share on 2026-08-18 under a Rule 10b5-1 Plan.

How many stock options does ARTV’s Subhashis Banerjee hold after the reported transactions?

After the reported Form 4 transactions, Subhashis Banerjee holds 79,571 stock options. These options stem from a grant that vested 25% on April 8, 2026, with the balance vesting monthly over the subsequent 36 months.

At what prices did ARTV’s Chief Medical Officer exercise and sell shares?

Subhashis Banerjee exercised options at an exercise price of $1.92 per share and then sold the resulting 429 ARTV common shares at $12.00 per share on 2026-08-18, according to the Form 4 filing.

Were ARTV insider transactions on this Form 4 made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the transactions occurred pursuant to a Rule 10b5-1 Plan that Subhashis Banerjee adopted on May 14, 2026, indicating a pre-arranged trading program for these trades.

What are the vesting terms of the ARTV stock options exercised by Subhashis Banerjee?

The option grant vested 25% and became exercisable on April 8, 2026, with the remaining shares vesting and becoming exercisable at 1/36th per month over the following 36 months, as described in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Banerjee Subhashis

(Last)(First)(Middle)
C/O ARTIVA BIOTHERAPEUTICS, INC.
5505 MOREHOUSE DRIVE, SUITE 100

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/18/2026M(1)429A$1.92145,392D
Common Stock08/18/2026S(1)429D$12144,963D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$1.9208/18/2026M(1)429 (2)04/07/2035Common Stock429$079,571D
Explanation of Responses:
1. The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.
2. 25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.
/s/ Andrew Cronauer, Attorney-in-Fact08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)